Studies on the heterogeneity of urinary human chorionic gonadotropin molecules by radio receptor assay and radio immunoassay

Kushiki, N.; Fuzishima, K.; Kinoshita, T.; Ino, H.; Naka, O.

Folia Endocrinologica Japonica 55(9): 1076-1088

1979


Accession: 006517410

Download citation:  
Text
  |  
BibTeX
  |  
RIS

Article/Abstract emailed within 1 workday
Payments are secure & encrypted
Powered by Stripe
Powered by PayPal

Abstract
A sensitive bioassay (radioreceptor assay: RRA) for urinary hCG ) ratio of urinary hCG in pregnant and trophoblastic diseased women was examined. The urine of women with normal pregnancies was studied for quantitative and qualitative differences among hCG molecules by gel filtration on a Sephadex G-100, and each fraction was measured by RRA and RIA. The RRA sensitivity was 4 ng/ml with a precision of 0.03. The intra-assay coefficient of variation and that for interassay were 2-10% and 12.1%, respectively. There was a complete lack of cross-reaction with prolactin, hCG.alpha., hCG.beta. and follitropin; this apparently indicated a high RRA specificity. Receptor reactive hCG in urine throughout pregnancy showed a major peak in the 10th wk and declined, but remained fairly constant until the 31st wk of pregnancy. The RRA/RIA ratio in urinary hCG of normal pregnancies was highest in the 1st trimester and lower in the 2nd and 3rd trimesters. The average value throughout gestation was 2.04 .+-. 0.18 (SE), which was .apprx. 2 times greater than that (1.08 .+-. 0.11 (SE)) of trophoblastic diseases (P < 0.01). The RRA/RIA ratio in the patients with trophoblastic tumors was highest in the hydatidiform mole and lowest in the chorioepithelioma. When the urine of normal pregnancies was gel filtrated on a Sephadex G-100, receptor active hCG molecules were present in urine of the 1st and 2nd trimesters. Apparently the RRA/RIA ratio in urinary hCG of normal pregnancies was distinct from that of women with trophoblastic tumors. This would assist in an early diagnosis and the treatment of successive trophoblastic disease in follow-ups of patients with hydatidiform mole.